Bill White
About Bill White
Bill White is an independent director at Q/C Technologies, Inc. (QCLS). He is 64 years old and has a finance background with an education from Washington State University . His service on the QCLS board is reflected in company filings listing his beneficial ownership and recent director equity grants .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sidus Space (Nasdaq: SIDU) | Chief Financial Officer | 2024–2025 | Finance leadership |
| ProPhase Labs (Nasdaq: PRPH) | Chief Financial Officer | 2022–2023 | Finance leadership |
| Intellicheck (Nasdaq: IDN) | CFO/COO | 2012–2022 | Operations and audit-facing expertise |
| FocusMicro, Inc. | CFO/COO | 2000–2012 | Operational finance |
| Women’s Wear Daily (WWD) | Director of Finance | 1991–2000 | Corporate finance |
External Roles
| Company | Role | Notes |
|---|---|---|
| COMSovereign Holding Corp. | Independent Director | Listed by MarketScreener network profile |
| TNF Pharmaceuticals, Inc. | Board Member / Audit Committee Chair | Listed on LinkedIn (company mapping shows Q/C Technologies link) |
Board Governance
- Board actions and capital structure oversight: In 2025, the Board recommended and shareholders approved (a) the Issuance Proposal authorizing significant potential equity issuance (>20%), (b) an increase in shares under the 2021 Equity Incentive Plan to 1,400,000, and (c) a reverse stock split authority (1-for-2 to 1-for-250) .
- Investor rights and board composition: Agreements with preferred holders in 2025 entitle a Required Holder to nominate one director (subject to Nominating & Governance Committee approval), and the company committed to reduce board size to no more than six directors by the 2025 annual meeting .
- Committee assignments: Company filings in the special proxy and 10-Q do not disclose committee rosters; LinkedIn lists Bill White as Audit Committee Chair (external source) . Internal references to “audit committee” appear in officer certifications but not membership listings .
Fixed Compensation
- Cash retainers, committee chair fees, and meeting fees for directors are not disclosed in the 2025 special proxy or 10-Q. No director cash compensation table was provided; therefore, items are omitted.
Performance Compensation
| Grant Type | Grant Date | Number of Units | Vesting / Conditions | Source |
|---|---|---|---|---|
| RSUs (Initial Grants) | Oct 3, 2025 | 2,161 | Issued and fully vested on Grant Date | |
| RSUs (Additional Grants) | Contingent as of Oct 3, 2025 | 22,839 | To be issued and fully vest upon stockholder approval of Plan increase (approved Nov 14, 2025) | |
| Options | Outstanding as of Record Date | 33 | Exercisable within 60 days of Record Date |
Performance Metrics Framework (Plan and historical RSUs):
- The 2021 RSU program features vesting based on market capitalization thresholds ($500M, $750M, $1,000M) and stock price conditions ($150), plus change-in-control and certain termination accelerations; as of Sep 30, 2025, none of these milestones had been met .
- The 2021 Equity Incentive Plan permits performance awards tied to metrics including cash flow, revenues, EBITDA, EPS, stock price, market share, TSR, and other operational KPIs, with committee certification of goal attainment .
Other Directorships & Interlocks
| Organization | Overlap Type | Notes |
|---|---|---|
| COMSovereign Holding Corp. | External directorship | Independent Director per MarketScreener profile |
| TNF Pharmaceuticals, Inc. | External directorship | Board Member / Audit Chair per LinkedIn; company linkage shown to Q/C Technologies |
No specific interlocks with QCLS competitors/customers are disclosed in company filings; items omitted.
Expertise & Qualifications
- Financial leadership: CFO/COO experience across public companies (Intellicheck, ProPhase Labs, Sidus Space) demonstrates audit, controls, and capital markets proficiency .
- Audit and governance: Lists Audit Committee chair experience externally; company filings do not enumerate committee memberships .
- Education: Washington State University .
Equity Ownership
| Security | Amount | Notes |
|---|---|---|
| Common Stock (direct) | 24 | Direct holdings |
| RSUs (unvested/vested at Record Date) | 2,161 | As of Record Date; aligns with Oct 3 initial grant |
| Options (exercisable ≤60 days) | 33 | Short-term exercisable options |
| Total counted in beneficial ownership | 2,218 | Aggregate under SEC beneficial ownership rules |
No disclosures on pledged shares, hedging, or ownership guideline compliance were found in the special proxy; items omitted.
Governance Assessment
- Alignment and incentives: Bill White’s equity exposure is primarily through RSUs and small option grants; direct common ownership is de minimis (24 shares), suggesting alignment relies on performance/equity vesting rather than cash retainers (not disclosed) .
- Dilution and capital structure oversight: The Board recommended, and shareholders approved, significant potential dilution via the Issuance Proposal, plan share increase, and reverse split authority—signals of aggressive capital raising posture and restructuring. This elevates the importance of audit and governance oversight to protect minority shareholders amid complex preferred/warrant structures with anti-dilution features .
- Investor influence on governance: 2025 agreements entitle a Required Holder to nominate a director (subject to committee approval) and reduce board size to ≤6, indicating negotiated investor influence that the Nominating & Governance Committee must manage to preserve independence .
- Clawback and controls: The equity plan provides for recoupment in event of financial restatement and outlines robust performance criteria governance, consistent with governance best practices; however, specific clawback trigger history and enforcement are not disclosed .
RED FLAGS
- Significant dilution risk and complex preferred/warrant mechanics (price-based anti-dilution, floor prices) that can materially impact common shareholders; requires vigilant audit and board oversight .
- External investor nomination rights to the board (post-2025 amendments) could pressure independence if not carefully managed by the Nominating & Governance Committee .
Note: Committee memberships, attendance rates, cash compensation detail, and say-on-pay results are not disclosed in the 2025 special proxy or recent 10-Q; these items are omitted due to lack of filing detail.